All In Biotech

Drug Trial Radar · NCT07610473

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Draig Therapeutics LtdIndustry
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • DT-101Drug

    DT-101

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 56Time frame: from enrolment to day 56

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Draig Clinical Site

    Phoenix, Arizona · Recruiting

  • Draig Clinical Site

    Little Rock, Arkansas · Recruiting

  • Draig Clinical Site

    Bellflower, California · Recruiting

  • Draig Clinical Site

    Costa Mesa, California · Recruiting

  • Draig Clinical Site

    Lafayette, California · Recruiting

  • Draig Clinical Site

    Hialeah, Florida · Recruiting

  • Draig Clinical Site

    Orlando, Florida · Recruiting

  • Draig Clinical Site

    Orlando, Florida · Recruiting

  • Draig Clinical Site

    Tampa, Florida · Recruiting

  • Draig Clinical Site

    Tampa, Florida · Recruiting

  • Draig Clinical Site

    Decatur, Georgia · Recruiting

  • Draig Clinical Site

    Chicago, Illinois · Recruiting

  • Draig Clinical Site

    Skokie, Illinois · Recruiting

  • Draig Clinical Site

    Boston, Massachusetts · Recruiting

  • Draig Clinical Site

    New York, New York · Recruiting

  • Draig Clinical Site

    New York, New York · Recruiting

  • Draig Clinical Site

    Columbus, Ohio · Recruiting

  • Draig Clinical Site

    Allentown, Pennsylvania · Recruiting

  • Draig Clinical Site

    Media, Pennsylvania · Recruiting

  • Draig Clinical Site

    DeSoto, Texas · Recruiting

  • Draig Clinical Site

    Fort Worth, Texas · Recruiting

  • Draig Clinical Site

    Bellevue, Washington · Recruiting

  • Draig Clinical Site

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.